Biogen Inc. recently announced data that included extended results from its earlier Phase 3b NOVA study on the administration of natalizumab and the evaluation of the drugs Tysabri® and Vumerity. …
Welcome to Study of the Week from Patient Worthy. In this segment, we select a study we posted about from the previous week that we think is of particular interest…
A recent article from Healthline highlighted the similarities and differences between two neurological diseases, myasthenia gravis (MG) and multiple sclerosis (MS). Myasthenia Gravis Deriving from the Greek and Latin words…
In 2019, the United States approved Vumerity (diroximel fumarate) to treat adult patients with relapsing-remitting (R/R) multiple sclerosis (MS). Now, two years later, the European Union has approved this…
Atara Therapeutics has released data from its Phase 1 open-label extension (OLE) trial of ATA188, a treatment for progressive multiple sclerosis (MS). This allogeneic T-cell immunotherapy targets B cells and…
The 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) was held last week from the 13th to the 15th. This event is the largest…
Kristin woke up the morning of her 19th birthday with a startling realization: she was unable to speak. It was hard to describe the feeling, but when she tried to…
Actress, dancer, and producer Christina Applegate is best known for her roles in Dead to Me, Married...with Children, Samantha Who?, and Up All Night. But now, she has revealed a new role: a member…
A new study published in the journal Scientific Reports has helped explain the differences between neuromyelitis optics spectrum disorder (NMOSD) after optic neuritis (ON) and multiple sclerosis (MS). Although previous studies have…
According to a story from express.co.uk, multiple sclerosis (MS) is a neurological illness that can have major impacts on the lives of its patients. As a condition that can be…
In a review posted on dovepress.com, monoclonal antibodies have established themselves as an important tool in the management of multiple sclerosis in both the relapsing-remitting form and the progressive form.…
Have you ever heard of isoflavone? Well, isoflavone is part of a class of phytoestrogens, or plant-based compounds which resemble estrogen. According to Medical XPress, research from Dr. Ashutosh Mangalam,…
Komodo Health and PicnicHealth have just announced that they have partnered together in effort to combine their data and better serve patients. This data will then be made accessible to…
According to Multiple Sclerosis News Today, the European Commission (EC) recently approved PONVORY (ponesimod) for the treatment of adult patients with relapsing and remitting (R/R) or active secondary progressive (SP)…
According to an article in Biospace, Biogen, a biotechnology company headquartered in Cambridge, Massachusetts, presented new data on its multiple sclerosis (MS) therapies at the virtual Meeting of the American…
Currently, multiple sclerosis (MS), an autoimmune and neurological disorder, is considered either progressive or relapsing-remitting. But could there be additional subtypes? According to new research, yes. As explained in Medical…
Around 30% of all patients with relapsing-remitting multiple sclerosis (RRMS) experience some type of cognitive impairment or decline at the time of diagnosis. Around 50% of patients experience some of…
When I sat down with 38-year-old Adam Kemble for our interview, there was one point that he really drove home: “You have the opportunity to choose what you let define…
On March 11, 2021, Patient Worthy attended an educational seminar hosted by the Cleveland Clinic titled Neuromyelitis Optica Spectrum Disorder (NMOSD): Educational Seminar for Patients, Family Members and Caregivers Focus…
From February 25-27, the Americas Committee for Treatment and Research in Multiple Sclerosis will run its ACRTIMS Forum 2021, according to BioSpace. At this forum, Clene Inc. will present interim…
How much does our diet play a role in underlying health issues? In some cases, it might play an even larger part than we believe. As recently reported in Yale…
The National Institute for Health and Clinical Excellence (NICE), an agency under the UK's National Health Service (NHS), has recently rejected Zeposia. Zeposia is an oral, multiple sclerosis (MS) treatment…
In early January 2021, pharmaceutical company Astellas Pharma Inc. ("Astellas") shared that its New Drug Application (NDA) and supplemental NDA for Myrbetriq (mirabegron) received Priority Review status from the…
Are you looking to get more involved in research, treatment, and awareness? Well, here's your chance! The University of Georgia (UGA) is currently seeking participants to join their study,…
Neurodegenerative diseases such as Parkinson’s, Alzheimer’s, and multiple sclerosis are disorders that mostly affect the neurons located in the brain. These diseases are incurable, resulting in the death of nerve…
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
